Please login to the form below
CD3
This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.
Amgen pledges $1.5bn for CytomX preclinical cancer drugs
bispecific) antibody targeting the epidermal growth factor receptor (EGFR) and CD3 receptor that has come out of CytomX’s Probody platform. ... CytomX will handle the early stages of clinical development of the EGFR/CD3 Probody, with Amgen getting
Latest news
-
Celgene bolsters blood cancer portfolio with $600m EngMab buy
At last year's American Society of Hematology (ASH) meeting, EngMab gave two presentations showing how antibodies binding the CD3 receptor on T cells and BCMA were able to selectively kill
-
Amgen leukaemia drug gets FDA priority review
Blinatumomab - which targets CD19- and CD3-expressing cells - is also in phase II trials for non-Hodgkin's lymphoma (NHL) and, according to analysts at JP Morgan, could become a ... Amgen's BiTE pipeline also includes anti-EpCAM (epithelial cell adhesion
-
Amgen files breakthrough leukaemia antibody in US
BiTE antibodies are designed to exert anticancer effects by directing the body's cell-destroying T lymphocytes to attack tumour cells, and in the case of blinatumomab targets CD19- and
-
GSK signs $500m-plus technology deal with Immunocore
against CD3 that can activate the immune system to kill the cells.
-
Global academic research alliance to speed drug development
Belgium's Centre for Drug Design and Discovery (CD3), and the UK's Medical Research Council (MRC) Technology and Cancer Research Technology (CRT) complete the list of founding members, all of
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Taking a lean and careful approach
Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,
-
Deal Watch June 2016
Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding
-
Pharma deals during December 2014
platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.
-
Deal Watch table for August 2014
187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
-
Pharma deals during February 2014
CD123 and CD3.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences
Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Editor – Medical Education Agency – Bucks
-
Salary TBC
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
-
Scientific Director
-
Great salary and bebefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
-
Senior Programme Executive
-
Salary TBC
- Account Manager – Med Comms – London
-
Salary TBC
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
-
Senior Medical Writer
-
Great salary and bebefits
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
Subscribe to our email news alerts
PMHub
Redline Strategic
We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
